Speaker(s): 

Amanda Miller, PharmD, Staff Member, Geisinger - has nothing to disclose.

Emma Wysocki, PharmD, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Daniel Longyhore, PharmD, Ed.D., BCACP, Staff Member, Geisinger - has nothing to disclose.   

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• describe prior failed and approved pharmacologic RSV prevention strategies for infants, children, and adults.
• summarize current recommendations for nirsevimab and describe experience during the 2023-2024 RSV season.
• discuss considerations for RSV-prevention going into the 2024-2025 RSV season and beyond.
• review current adult guidelines regarding RSV vaccinations.  
• analyze and compare phase 3 trials for available RSV vaccinations. 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, Ed.D., BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH; Lisabeth Karetsky, CPhT and Nichole Varela Gonzalez have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.